The efficacy of carvedilol in improving cardiac function and survival in patients with anthracycline-induced cardiotoxicity: a comprehensive systematic review and meta-analysis
Carvedilol appears to protect cardiac function in patients undergoing ANT therapy, though it does not significantly impact mortality. Further research is needed to determine optimal dosing, timing, and long-term survival benefits.
Authors
- Riya Bhagwan (ORCID: https://orcid.org/0009-0006-5504-052X)
- Neha Malik
- Rayyan Nabi (ORCID: https://orcid.org/0009-0001-9409-652X)
- Najaf Ahmed Rajpar
- Sanya Ashraf Khaskheli
- Raheel Ahmed (ORCID: https://orcid.org/0000-0002-6505-2851)
- Ayesha Amir Basra
- Aamna Rehman
- Sabahat Ul Ain Munir Abbasi
- Kalpana Singh
- Shehdev Meghwar
Institutions
- Liaquat University of Medical & Health Sciences (PK)
- Riphah International University (PK)
- Allama Iqbal Medical College (PK)
- Freeman Hospital (GB)
- Farooq Hospital (PK)
- Dow University of Health Sciences (PK)
- Royal Brompton Hospital (GB)
- Hamad Medical Corporation (QA)
Publication Details
- Journal
- IJC Heart & Vasculature
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1016/j.ijcha.2025.101862
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00